Rare disease at an inflection point: Why the next wave will be won on strategic insight
Rare disease has moved beyond a science-led opportunity into a strategy-led one. As more programmes reach the clinic and regulatory frameworks mature, the advantage is shifting toward companies that can identify inflection points early, before value is fully priced in. For business development teams, this marks a fundamental change. The question is no longer whether rare disease assets will attract interest, but which signals matter most when prioritising partnerships, acquisitions, or internal investment decisions.
Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making.
BioMarin’s acquisition of Amicus consolidated its leadership in enzyme replacement therapies, pairing complementary portfolios while leveraging BioMarin’s established global commercial infrastructure to significantly expand the reach and impact of Amicus’ therapies worldwide.
Novartis’ acquisition of Avidity signals increasing confidence in precision RNA modalities for neuromuscular disorders while strategically diversifying its neuromuscular rare disease portfolio beyond gene therapy.
Eli Lilly’s acquisition of Prevail reflects expanding interest in genetically defined neurodegenerative diseases. This move also establishes a gene therapy programme at Lilly, anchored by Prevail’s neuroscience portfolio, and broadens Lilly’s commitment to novel modalities for otherwise fatal genetic forms of neurodegeneration.
In contrast to these examples of acquisition-led expansion, Sarepta’s evolution into a scaled commercial organisation illustrates that focused rare disease companies can mature into durable partners or acquisition targets when execution aligns with disease expertise.
New company models such as Mendra (launched in January 2026 and founded by former BioMarin leadership) are also emerging with platform-driven strategies designed for multi-indication expansion. For business development teams, this means the universe of potential partners is both growing and becoming more sophisticated, increasing competition for high-quality assets.
Regulatory signals are reshaping rare disease development
In rare disease, regulatory signals are increasingly guiding scientific strategy well before pivotal data is generated. The FDA’s proposed Rare Disease Evidence Principles (RDEP) process reflects a more explicit recognition that, in very small, genetically defined populations with high unmet need, traditional development paradigms may be insufficient to fully capture treatment effect.
Importantly, RDEP does not alter the statutory standard for safety and efficacy, but it provides greater clarity around how substantial evidence of effectiveness may be established, often through a single adequate and well-controlled study supported by a broader body of confirmatory evidence. This may include pathophysiology-based biomarkers, pharmacodynamic data, relevant non-clinical models, natural history studies, and other supportive clinical data, particularly when randomised or placebo-controlled trials are impractical.
By formalising expectations for how diverse data sources can be evaluated together, RDEP is shaping upstream scientific decisions around endpoint selection, trial design, and evidence generation well before pivotal studies begin. This shift is further reinforced by the FDA’s Rare Disease Day, which it held on 23rd February 2026, underscoring earlier and more structured engagement among sponsors, review teams, patients, and disease communities, positioning regulatory dialogue itself as a source of forward-looking insight into evidence standards and regulatory expectations, often well ahead of formal guidance.
In parallel, the recent approval of the first non-profit-sponsored gene therapy of Fondazione Telethon’s Waskyra (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome underscores a regulatory environment that is increasingly adaptive to the realities of ultra-rare disease development. From a competitive intelligence perspective, these signals help explain why certain programmes advance despite unconventional designs, while others stall despite strong biological rationale.
In an increasingly crowded rare disease landscape, the ability to interpret regulatory intent, not just published outcomes, is becoming a critical differentiator.
New modalities raise new scientific and safety questions
While regulators have demonstrated increasing flexibility in how evidence is evaluated, patient safety remains paramount. Regenxbio recently announced a clinical hold for its AAV gene therapy RGX-111 for MPS I (Hurler syndrome) after preliminary analysis of one case of neoplasm (intraventricular CNS tumour) in a Phase 1/2 trial participant. Given similarities between programmes, the company’s AAV gene therapy RGX-121 programme for MPS II (Hunter syndrome) was also placed on clinical hold, just weeks ahead of its PDUFA date, raising questions around acceptable risk thresholds in populations with limited or no therapeutic alternatives.
Similarly, patient deaths following treatment with Sarepta’s Elevidys, and the continued clinical hold in non-ambulatory patients as enhanced immunosuppression protocols are evaluated, underscore the FDA’s continued focus on safety, even in settings of high unmet need. While Sarepta’s recent three-year follow-up data may help rebuild confidence in the programme, these developments highlight the growing importance of long-term safety monitoring in gene therapy.
As a result, evaluating rare disease programmes increasingly requires deeper scrutiny of vector biology, transgene expression dynamics, and immune responses. Long-term follow-up is no longer a downstream regulatory obligation – it has become a core component of scientific credibility and programme differentiation.
For competitive intelligence teams, these developments reinforce the need to look beyond top-line efficacy readouts – integrating safety signals, protocol amendments, and regulatory interactions to build a more complete assessment of true programme durability and risk.
Why competitive intelligence matters more than ever in rare disease
As rare disease becomes more competitive, information parity is disappearing.
In this environment, competitive intelligence moves beyond reporting past events to actively interpreting early scientific and regulatory signals, allowing organisations to separate durable innovation from transient signal well before consensus emerges.
Rare disease remains one of the most compelling areas for growth in pharma. But as the space matures, advantage will increasingly accrue to those who can convert complexity into clarity, faster than the market.
About the authors
Laksheeta Johari is a senior consultant with Lifescience Dynamics, with over 6 years of CI experience. She is involved as a project manager in CI projects across indications including rare diseases, with special attention to new developments across gene therapies. As an experienced project manager, she is focused on managing cross functional CI projects, and delivering high impact, strategic deliverables. Her experience spans all aspects of CI, including secondary research and conference coverage, through which she is able to generate insights and analyse the implications for her clients and their portfolio.
Sara Sukenik is a senior business analyst based in the New York office. Sukenik completed her PhD in Biomedical Engineering from the University of California at Davis where her research focused on developing a novel manufacturing method for protein-based therapeutics using plant cells. During her time at LSD, Sukenik has been deeply involved in projects focused on rare diseases, including secondary research, conference coverage, and primary research gathering.
